GE HealthCare Technologies Inc. (GEHC)
| Market Cap | 29.42B -10.6% |
| Revenue (ttm) | 20.98B +6.0% |
| Net Income | 1.91B -12.6% |
| EPS | 4.17 -12.4% |
| Shares Out | 454.89M |
| PE Ratio | 15.51 |
| Forward PE | 12.97 |
| Dividend | $0.14 (0.22%) |
| Ex-Dividend Date | Apr 2, 2026 |
| Volume | 4,926,487 |
| Open | 63.80 |
| Previous Close | 63.81 |
| Day's Range | 63.58 - 64.78 |
| 52-Week Range | 58.75 - 89.77 |
| Beta | 0.87 |
| Analysts | Buy |
| Price Target | 79.72 (+23.27%) |
| Earnings Date | Apr 29, 2026 |
About GEHC
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, an... [Read more]
Financial Performance
In 2025, GEHC's revenue was $20.63 billion, an increase of 4.84% compared to the previous year's $19.67 billion. Earnings were $2.08 billion, an increase of 4.57%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for GEHC stock is "Buy." The 12-month stock price target is $79.72, which is an increase of 23.27% from the latest price.
News
GE HealthCare receives 510k clearance from U.S. FDA for MIM Contour ProtegeAI+
GE HealthCare (GEHC) announced it has received 510(k) clearance from the United States Food and Drug Administration, FDA, for MIM Contour ProtegeAI+ 2.0, an AI-enabled auto-contouring software to assi...
GE HealthCare receives FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0, advancing AI-enabled radiation therapy planning with expanded clinical capabilities
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for MIM Contour ProtégéAI+™ 2.0, an AI...
GE HealthCare Technologies Transcript: Jefferies Global Healthcare Conference 2026
Orders and backlog reached record levels, with robust demand and revenue growth driven by existing products. Inflation and memory chip costs led to a guidance reduction, but buffers and mitigation strategies are in place. New product launches and pipeline innovations are expected to accelerate growth, while Flyrcado and strategic M&A remain key priorities.
GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations
CHICAGO--(BUSINESS WIRE)--As theranostics adoption acceleratesi and radiopharmaceutical demand grows,ii healthcare systems are under increasing pressure to scale nuclear medicine operations while impr...
GE HealthCare upgraded to Neutral from Sell at UBS
UBS upgraded GE HealthCare (GEHC) to Neutral from Sell with a price target of $69, down from $75. The firm cites valuation for the upgrade with the shares down 30%…
GE HealthCare Technologies Transcript: Bank of America Global Healthcare Conference 2026
Guidance was reduced due to inflation and supply chain pressures, but EPS growth and margin improvement are expected through cost initiatives, pricing actions, and new product launches. Strategic restructuring, robust innovation, and strong market demand support a positive long-term outlook.
GE HealthCare to highlight AI-enabled solutions at ESTRO 2026 Congress
At the European Society for Radiotherapy and Oncology 2026 Congress in Stockholm, GE HealthCare (GEHC) will highlight a portfolio of AI-enabled solutions designed to support clinicians across radiatio...
ESTRO 2026 Congress: GE HealthCare to spotlight AI-enabled solutions to advance precision care across radiation therapy and image-guided interventions
CHICAGO--(BUSINESS WIRE)--At the European Society for Radiotherapy and Oncology (ESTRO) 2026 Congress in Stockholm, GE HealthCare (Nasdaq: GEHC) will highlight a portfolio of AI-enabled solutions desi...
GE HealthCare highlights next-generation SIGNA MR systems
GE HealthCare (GEHC) announced advancements in research tools and MR systems that aim to accelerate discovery, strengthen collaboration across research programs, and turn innovation into meaningful cl...
GE HealthCare next-gen SIGNA MR technology helps advance research discovery and translate innovation into clinical impact
CHICAGO--(BUSINESS WIRE)--As the global magnetic resonance (MR) community convenes for the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE HealthCare (Nasdaq: ...
GE HealthCare Technologies Transcript: AGM 2026
The meeting reviewed strong 2025 financials, robust innovation investments, and strategic segment changes. All director nominees and proposals passed, with ongoing mitigation of tariffs and inflation highlighted as key challenges. Demand remains strong across global markets.
GE HealthCare Technologies Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of GE HealthCare Technologies Inc. (NASDAQ: GEHC). The investigation focuses...
GE HealthCare price target lowered to $85 from $89 at Oppenheimer
Oppenheimer analyst Suraj Kalia lowered the firm’s price target on GE HealthCare (GEHC) to $85 from $89 and keeps an Outperform rating on the shares following quarterly results. The firm…
GE HealthCare price target lowered to $80 from $85 at Evercore ISI
Evercore ISI lowered the firm’s price target on GE HealthCare (GEHC) to $80 from $85 and keeps an Outperform rating on the shares.
GE HealthCare price target lowered to $65 from $80 at JPMorgan
JPMorgan analyst Robbie Marcus lowered the firm’s price target on GE HealthCare (GEHC) to $65 from $80 and keeps a Neutral rating on the shares.
GE HealthCare price target lowered to $65 from $80 at Citi
Citi lowered the firm’s price target on GE HealthCare (GEHC) to $65 from $80 and keeps a Neutral rating on the shares.
GE HealthCare price target lowered to $78 from $87 at Barclays
Barclays analyst Matt Miksic lowered the firm’s price target on GE HealthCare (GEHC) to $78 from $87 and keeps an Equal Weight rating on the shares. The company reported a…
GE HealthCare downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst David Roman downgraded GE HealthCare (GEHC) to Neutral from Buy with a price target of $65, down from $81, following the Q1 report. The company’s reduced 2026E…
GE HealthCare price target lowered to $65 from $80 at Citi
Citi lowered the firm’s price target on GE HealthCare (GEHC) to $65 from $80 and keeps a Neutral rating on the shares. Expectations were low going into the print, but…
GE HealthCare price target lowered to $80 from $98 at Stifel
Stifel lowered the firm’s price target on GE HealthCare (GEHC) to $80 from $98 and keeps a Buy rating on the shares. The list of positives underpinning GE HealthCare’s Q1…
GE HealthCare falls -13.4%
GE HealthCare (GEHC) is down -13.4%, or -$9.21 to $59.29.
GE HealthCare Technologies Earnings Call Transcript: Q1 2026
Q1 revenue grew 2.9% year-over-year to $5.1B, with strong global demand but profit pressured by inflation and a supplier recall. Guidance for 2026 EPS and margins was reduced, but sales growth and innovation momentum remain strong.
GE HealthCare Technologies Slides: Q1 2026
GE HealthCare Technologies has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
GE HealthCare Technologies Earnings release: Q1 2026
GE HealthCare Technologies released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
GE HealthCare Technologies Quarterly report: Q1 2026
GE HealthCare Technologies has published its Q1 2026 quarterly earnings report on April 29, 2026.